{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:23:46Z","timestamp":1787163826459,"version":"build-2736575974"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosdigitalhealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Digit Health"],"abstract":"<jats:p>Artificial intelligence (AI) tools are entering clinical practice at unprecedented speed. 1,357 AI\/ML-enabled medical devices have received U.S. FDA clearance or approval, yet their impact on patient outcomes remains largely untested. We conducted a systematic analysis of all FDA-cleared AI\/ML-enabled medical devices through December 5, 2025 using the FDA device database and the ACR Data Science Institute catalogue, with linked searches of ClinicalTrials.gov and PubMed to identify registered trials and publications. Of 1,357 cleared AI devices, only 34 (2.5%) were linked to registered prospective trials, 12 (0.9%) posted results, 12 (0.9%) had peer-reviewed publications, and only 3 (0.2%) evaluated patient-centered outcomes such as mortality, morbidity, or readmissions. Most studies (62%) employed observational designs with small, homogenous cohorts, limited subgroup analyses, and frequent exclusion of vulnerable populations. Structural barriers (including misaligned financial incentives, reliance on predicate-based regulatory pathways, and logistical challenges of multi-center trials) discourage rigorous evaluation. Internationally, FDA clearance often functions as a gateway for global deployment, raising ethical concerns when under-validated tools are introduced into low- and middle-income countries without contextual validation or safeguards. Regulatory approval has outpaced clinical validation, creating an ecosystem where innovation advances without accountability. The finding that only 0.2% of cleared devices have undergone evaluation for patient-centered outcomes reveals a profound validation gap and points to the need for evidence standards capable of keeping pace with the speed of regulatory clearance. Readiness should no longer be defined by FDA clearance alone, but by demonstrated, durable, and equitable benefit to patients.<\/jats:p>","DOI":"10.1371\/journal.pdig.0001597","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:23:34Z","timestamp":1787160214000},"page":"e0001597","update-policy":"https:\/\/doi.org\/10.1371\/journal.pdig.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["1,357 AI medical devices cleared, 3 actually tested on patient outcomes"],"prefix":"10.1371","volume":"5","author":[{"given":"Rawan","family":"Abulibdeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-6178","authenticated-orcid":true,"given":"Sebasti\u00e1n Andr\u00e9s","family":"Cajas Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo Anthony","family":"Celi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gorijavolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nura","family":"Izath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torleif","family":"Markussen Lunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"pdig.0001597.ref001","author":"US Food and Drug Administration","year":"2024"},{"issue":"4","key":"pdig.0001597.ref002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.8052","article-title":"Generalizability of FDA-approved AI-enabled medical devices for clinical use","volume":"8","author":"D Windecker","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pdig.0001597.ref003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2214\/AJR.21.27071","article-title":"Artificial intelligence (AI) for screening mammography, from the AJR special series on AI applications","volume":"219","author":"LR Lamb","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"pdig.0001597.ref004","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(23)00298-X","article-title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study","volume":"24","author":"K L\u00e5ng","year":"2023","journal-title":"Lancet Oncol"},{"issue":"14","key":"pdig.0001597.ref005","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001201","article-title":"Use of artificial intelligence in improving outcomes in heart disease: a scientific statement from the American Heart Association","volume":"149","author":"AA Armoundas","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"pdig.0001597.ref006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2024.05.003","article-title":"Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC state-of-the-art review","volume":"84","author":"R Khera","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"pdig.0001597.ref007","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.21037\/jtd-24-1793","article-title":"State-of-the-art artificial intelligence methods for pre-operative planning of cardiothoracic surgery and interventions: a narrative review","volume":"17","author":"QJ Mank","year":"2025","journal-title":"J Thorac Dis"},{"key":"pdig.0001597.ref008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41746-020-00324-0","article-title":"The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database","volume":"3","author":"S Benjamens","year":"2020","journal-title":"NPJ Digit Med"},{"issue":"1","key":"pdig.0001597.ref009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41746-024-01270-x","article-title":"A scoping review of reporting gaps in FDA-approved AI medical devices","volume":"7","author":"V Muralidharan","year":"2024","journal-title":"NPJ Digit Med"},{"issue":"3","key":"pdig.0001597.ref010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/electronics13030498","article-title":"FDA-approved artificial intelligence and machine learning (AI\/ML)-enabled medical devices: an updated landscape","volume":"13","author":"G Joshi","year":"2024","journal-title":"Electronics"},{"key":"pdig.0001597.ref011","article-title":"Early recalls and clinical validation gaps in artificial intelligence\u2013enabled medical devices","volume":"6","author":"B Lee","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"8","key":"pdig.0001597.ref012","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamainternmed.2021.2626","article-title":"External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients","volume":"181","author":"A Wong","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"6","key":"pdig.0001597.ref013","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2018-0255","article-title":"Concordance study between IBM Watson for Oncology and clinical practice for patients with cancer in China","volume":"24","author":"N Zhou","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"pdig.0001597.ref014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00146-020-00945-9","article-title":"Concordance as evidence in the Watson for Oncology decision-support system","volume":"35","author":"A Tupasela","year":"2020","journal-title":"AI & Soc"},{"key":"pdig.0001597.ref015","author":"US Food and Drug Administration","year":"2025"},{"key":"pdig.0001597.ref016","author":"American College of Radiology Data Science Institute","year":"2025"},{"key":"pdig.0001597.ref017","author":"U S National Library of Medicine","year":"2025"},{"issue":"10","key":"pdig.0001597.ref018","doi-asserted-by":"crossref","first-page":"100347","DOI":"10.1016\/j.patter.2021.100347","article-title":"Addressing bias in big data and AI for health care: a call for open science","volume":"2","author":"N Norori","year":"2021","journal-title":"Patterns (N Y)"},{"issue":"11","key":"pdig.0001597.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000651","article-title":"Bias in medical AI: implications for clinical decision-making","volume":"3","author":"JL Cross","year":"2024","journal-title":"PLOS Digit Health"},{"issue":"1","key":"pdig.0001597.ref020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-019-1426-2","article-title":"Key challenges for delivering clinical impact with artificial intelligence","volume":"17","author":"CJ Kelly","year":"2019","journal-title":"BMC Med"},{"issue":"2","key":"pdig.0001597.ref021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/bmjinnov-2019-000359","article-title":"Bridging the implementation gap of machine learning in healthcare","volume":"6","author":"MG Seneviratne","year":"2019","journal-title":"BMJ Innov"},{"issue":"1","key":"pdig.0001597.ref022","article-title":"A novel maturity index for assessing medical device startups","volume":"6","author":"FJ Richmond","year":"2022","journal-title":"J Clin Transl Sci"},{"key":"pdig.0001597.ref023","author":"R Health","year":"2025"},{"key":"pdig.0001597.ref024","author":"P Desai","year":"2024"},{"key":"pdig.0001597.ref025","article-title":"FDA breakthrough device designation: clinical evidence and Medicare payment policies","author":"NK Prasad","year":"2024","journal-title":"Health Affairs Forefront"},{"issue":"40","key":"pdig.0001597.ref026","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012715","article-title":"Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study","volume":"97","author":"AC Roginiel","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"pdig.0001597.ref027","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacbts.2016.03.009","article-title":"Drugs, devices, and the FDA: Part 2: an overview of approval processes: FDA approval of medical devices","volume":"1","author":"GA Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"issue":"14","key":"pdig.0001597.ref028","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMra1512592","article-title":"An FDA viewpoint on unique considerations for medical-device clinical trials","volume":"376","author":"O Faris","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"pdig.0001597.ref029","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1007\/s11606-021-07316-0","article-title":"Experts\u2019 views on FDA regulatory standards for drug and high-risk medical devices: implications for patient care","volume":"37","author":"SS Dhruva","year":"2022","journal-title":"J Gen Intern Med"},{"key":"pdig.0001597.ref030","author":"U S Congress","year":"1962"},{"issue":"4","key":"pdig.0001597.ref031","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"NS Downing","year":"2014","journal-title":"JAMA"},{"key":"pdig.0001597.ref032","author":"U S Food and Drug Administration"},{"issue":"24","key":"pdig.0001597.ref033","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1001\/jama.2009.1899","article-title":"Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices","volume":"302","author":"SS Dhruva","year":"2009","journal-title":"JAMA"},{"key":"pdig.0001597.ref034","author":"U S Food and Drug Administration","year":"2025"},{"issue":"6","key":"pdig.0001597.ref035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1001\/jama.2015.8761","article-title":"Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011","volume":"314","author":"VK Rathi","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"pdig.0001597.ref036","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/healthcare13070701","article-title":"Bridging the gap: from AI success in clinical trials to real-world healthcare implementation-a narrative review","volume":"13","author":"RA El Arab","year":"2025","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"pdig.0001597.ref037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12992-020-00584-1","article-title":"Artificial intelligence in health care: laying the foundation for responsible, sustainable, and inclusive innovation in low- and middle-income countries","volume":"16","author":"H Alami","year":"2020","journal-title":"Global Health"},{"key":"pdig.0001597.ref038","author":"US Food and Drug Administration","year":"2023"},{"key":"pdig.0001597.ref039","author":"US Food and Drug Administration","year":"2021"},{"key":"pdig.0001597.ref040","author":"US Food and Drug Administration","year":"2021"},{"key":"pdig.0001597.ref041","author":"US Food and Drug Administration","year":"2023"},{"key":"pdig.0001597.ref042","unstructured":"International Medical Device Regulators Forum (IMDRF), SaMD Working Group. Software as a Medical Device (SaMD): Clinical Evaluation (IMDRF\/SaMD WG\/N41FINAL:2017). International Medical Device Regulators Forum; 2017. Published 21 September 2017 [cited 02 Sep 2025]."},{"key":"pdig.0001597.ref043","unstructured":"International Medical Device Regulators Forum (IMDRF), SaMD Working Group. Characterization Considerations for Medical Device Software and Software-Specific Risk (IMDRF\/SaMD WG\/N81 FINAL:2025). Geneva: International Medical Device Regulators Forum; 2025. IMDRF\/SaMD WG\/N81 FINAL:2025. Published January 29, 2025 [cited 02 Sep 2025]."},{"key":"pdig.0001597.ref044","author":"Medicines and Healthcare products Regulatory Agency (MHRA)"},{"key":"pdig.0001597.ref045","volume-title":"MDCG 2025-6: FAQ on interplay between the medical devices regulation & in vitro diagnostic medical devices regulation and the Artificial Intelligence Act","author":"Directorate-General for Health and Food Safety EC","year":"2025"},{"key":"pdig.0001597.ref046","doi-asserted-by":"crossref","DOI":"10.3389\/fcomp.2023.1187299","article-title":"Human-centered design and evaluation of AI-empowered clinical decision support systems: a systematic review","volume":"5","author":"L Wang","year":"2023","journal-title":"Front Comput Sci"},{"key":"pdig.0001597.ref047","author":"US Food and Drug Administration","year":"2024"},{"key":"pdig.0001597.ref048","doi-asserted-by":"crossref","DOI":"10.2196\/53616","article-title":"Benefits and Risks of AI in Health Care: Narrative Review","volume":"13","author":"M Chustecki","year":"2024","journal-title":"Interact J Med Res"},{"key":"pdig.0001597.ref049","volume-title":"Ethics and governance of artificial intelligence for health: WHO guidance","author":"World Health Organization","year":"2021"},{"issue":"1","key":"pdig.0001597.ref050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41746-022-00700-y","article-title":"Artificial intelligence for strengthening healthcare systems in low- and middle-income countries: a systematic scoping review","volume":"5","author":"T Ciecierski-Holmes","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"4","key":"pdig.0001597.ref051","doi-asserted-by":"crossref","DOI":"10.1007\/s13347-023-00687-8","article-title":"Artificial intelligence in the colonial matrix of power","volume":"36","author":"J Muldoon","year":"2023","journal-title":"Philos Technol"},{"key":"pdig.0001597.ref052","doi-asserted-by":"crossref","DOI":"10.1017\/dap.2024.75","article-title":"Artificial intelligence, digital colonialism, and the implications for Africa\u2019s future development","volume":"6","author":"AO Salami","year":"2024","journal-title":"Data Policy"},{"key":"pdig.0001597.ref053","volume-title":"Regulatory considerations on artificial intelligence for health","author":"World Health Organization","year":"2023"}],"container-title":["PLOS Digital Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pdig.0001597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:23:39Z","timestamp":1787160219000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pdig.0001597"}},"subtitle":[],"editor":[{"given":"Dukyong","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pdig.0001597","relation":{},"ISSN":["2767-3170"],"issn-type":[{"value":"2767-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}